Home › Funds › Lion Point Capital, LP › RPRX

Lion Point Capital, LP position in RPRX

ROYALTY PHARMA PLC · Health Care

Lion Point Capital, LP reported holding 21,400 shares of RPRX (ROYALTY PHARMA PLC) in its Q2 2026 13F filing — a position valued at US$1.2M, representing 5.74% of its reported portfolio and ranking #5 among its reported holdings. Lion Point Capital, LP has disclosed RPRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)21.40K sh
Reported value held$1.20M
Portfolio Weight5.74%
First reportedQ3 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lion Point Capital, LP's RPRX position evolved

Lion Point Capital, LP first disclosed a stake in RPRX in Q3 2025 at 21,400 shares (US$755K). The position peaked in Q2 2026 at 21,400 shares, worth US$1.2M. Across 4 filings, Lion Point Capital, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 21,400 shares valued at US$1.2M.

Quarter by quarter

QuarterSharesValueChange
Q3 2025 21.40K $754.99K New
Q4 2025 21.40K $826.90K Hold
Q1 2026 21.40K $1.03M Hold
Q2 2026 21.40K $1.20M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RPRX and 13F data

RPRX (ROYALTY PHARMA PLC) is a Health Care company. 50 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$601.4M), Baillie Gifford & Co (US$561.6M), Caledonia (Private) Investments Pty Ltd (US$323.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RPRX

All RPRX fund holders →

FAQ

How long has Lion Point Capital, LP held RPRX?

Lion Point Capital, LP has disclosed RPRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is Lion Point Capital, LP's current position in RPRX?

As of Q2 2026, Lion Point Capital, LP holds 21.40K shares of RPRX (ROYALTY PHARMA PLC), valued at $1.20M, representing 5.74% of its reported portfolio and ranking #5.

Has Lion Point Capital, LP been buying or selling RPRX?

In the latest 13F filing (Q2 2026), Lion Point Capital, LP held unchanged its position in RPRX. The position peaked in Q2 2026 at 21.40K shares.

Which other funds hold RPRX?

Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, Caledonia (Private) Investments Pty Ltd, among 50 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.